This paper is a revised and expanded version of a paper entitled 'Signal translational efficiency between mRNA expression and antibody-based protein expression for breast cancer and its subtypes from cell lines to tissue' presented
Introduction
Breast cancer is the most common cancer type in women worldwide with 1.7 million new cases and 450,000 deaths each year worldwide (Ferlay et al., 2015) . Clinical decisions on breast cancer therapies rely primarily on the assessment of estrogen-receptor (ER) expression, progesterone-receptor (PR) expression and human epidermal growth factor receptor 2 (HER2, also called ERBB2) amplification. At the molecular level, breast cancer has been traditionally classified into 4 groups: luminal A (ER/PR+, Her2−), luminal B (ER/PR+, Her2+), HER2 amplification (ER/PR−, Her2+), and basal-like (triple negative breast cancer (TNBC), ER/PR−, Her2−) tumours (Onitilo et al., 2009) . The ER or PR positive tumours (i.e., luminal A and B) usually receive endocrine (hormone) therapy as the standard treatment. The HER2 amplified tumours respond well to HER2 targeted therapy such as Trastuzumab. Conversely, basal-like/TNBC tumours are the most aggressive of all subtypes and result in a shorter survival time. TNBC currently lacksan FDA-approved targeted therapy, with chemotherapy still the standard treatment option. Recently, an enrichment of patients with germ line BRCA1 mutations have been observed in TNBC, suggesting therapeutic sensitivity to PARP inhibitors via a synthetic lethal approach (Ossovskaya et al., 2011) . Novel target identification for TNBC is a substantial focus for cancer molecular biology research (Bianchini et al., 2016) . Gene transcript (mRNA) or protein expression profiles have been utilised as biomarkers for cancer prognosis, though these biomarkers are not definitive drug targets. There are several mRNA and/or protein expression profile based biomarkers on the market, including the 21-gene recurrence score (Paik et al., 2004) Oncotype Dx ® , the 14-gene distant metastasis signature (Tutt et al., 2008) BreastOncPx ™ , the 97-gene histologic grade predictor (Sotiriou et al., 2006) High throughput microarrays and deep sequencing simultaneously detects the expression of thousands of genes to create a transcriptome-based landscape of cellular function. Gene-expression profiling studies have provided a molecular classification of breast cancer into clinically relevant subtypes, which have become important tools for predicting disease recurrence and response to different treatments and give new insights into various oncogenic pathways in different subtypes. On the other hand, gene transcript expression ultimately translates into protein. Proteome profiling reveals loss of proteome balance among cellular processes that mediate apoptosis, intercellular communication and pathway activities. Reverse phase protein arrays (RPPA) provide a moderate throughput antibody-based quantitative measurement of hundreds of signalling proteins or phosphoproteins in biological and clinical samples (Spurrier et al., 2008) . Comparing with mass spectrometry-based protein detection technology, RPPA has extraordinary sensitivity for the detection of low-abundance signalling proteins over a large linear range (Boellner and Becker, 2015) . Joint analyses of transcriptomic and proteomic results in tumour samples is one of the primary goals of cancer systems biology research. Due to the limitations of proteomics data, the systemic comparison between mRNAs and proteins is still in its infancy. Nagaraj et al. (2011) identified 10,255 different human proteins encoded by 9207 human genes in a single HeLa cell by mass spectrometry and compared mRNA-protein relation for the first time in year 2011. Until 2014, human tissue specific and antibody-based proteomics and transcriptomes were compared systematically (Fagerberg et al., 2014) . Most breast cancer molecular profiling studies, (Lacroix and Leclercq, 2004) and (Ross and Perou, 2001 ) have used either mRNA or protein expression in cell lines or primary tumours for systematic comparison of transcriptome variations.
Although breast cancer molecular subtypes have been extensively defined by means of gene expression profiling over the past decade, little is known as to how signalling pathways are differentially activated at the protein level. The limited findings can be found in reports by Gujral et al. (2013) and Sonntag et al. (2014) for RPPA data used in profiling phosphor-signalling networks and key signalling transduction pathways in breast tumours with specific subtypes. Gujral et al. (2013) measured the phosphorylation levels of 100 proteins with RPPA in 56 breast tumours and matched normal tissue samples in order to study the cross talk between oncogenesis and signalling pathways, with an emphasis on TNBC. Using RPPA, 128 breast cancer relevant proteins were measured among 109 hormone receptor-positive tumour samples (Sonntag et al., 2014) . While contributing to cancer proteomics research, the study did not assess signal transduction from mRNA to protein in breast tumours and their subtypes. Breast cancer cell lines are frequently used as models for in vitro research. In recent years, RPPA and mass spectrometry are increasingly utilised to identify breast cancer cell subtypes by profiling proteins and the phosphor proteome. By RPPA technology, Boyd et al. (2008) measured 100 proteins in 30 breast cancer cell lines to show distinct pathway activation between breast cancer subtypes. By mass spectrometry technology, Lawrence et al. (2015) performed proteomics analysis of 20 TNBC cells and four primary TNBC tumours, which covered 12,000 proteins. Although this significant work provided important information for drug target identification at the protein level for TNBC, no one has yet attempted to investigate the correlation between cell lines and primary tumours from gene expression to protein abundance between and within breast cancer subtypes systematically. Little is known about the signalling pathways differentially activated from transcriptome to proteome in the breast cancer subtypes.
Integrative transcriptomic and proteomic studies are helpful to understand the translational complexity between them. Many biomedical researchers have investigated the proportionality between mRNA expression and subsequent protein expression. Maier et al. (2009) and Vogel and Marcotte (2012) showed R-square of Pearson correlation coefficient of ~0.40, which implies that ~40% of cellular protein levels can be predicted from mRNA levels in human cells. Vogel et al. (2010) study has illustrated that sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line; however, an additional report (Akbani et al., 2014) , demonstrated that protein abundance and functions are poorly predicted by genomic and transcriptomic analysis in tumours. Although not every protein expression directly corresponds to its gene expression, in this study, we hypothesise that some protein levels can be well explained by their related mRNA level.
The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/ (Cancer Genome Atlas Network, 2012)) project provides a wealthy collection of RPPA protein array data for thousands tumour samples, along with matched genomic and transcriptomic data (Akbani et al., 2014) . The Cancer Cell Line Encyclopedia (CCLE, http://www. broadinstitute.org/ccle) provides detailed molecular characterisation of large panel of human cancer cell lines and has become a powerful tool for cancer drug treatment development. Together, CCLE and TCGA facilitate integrated mRNA/protein analyses in breast cancer cell lines, tumours, and most interestingly intrinsic subtypes. The potential actionable pathways with high signal transduction from mRNA to protein are analysed and compared in different subtype of breast cancer. Subtypes-specific signals reduced computationally for drug targets are discussed.
Results
207 human protein-coding genes from CCLE (Barretina et al., 2012) and Gordon Mills Lab in 33 breast cancer cell lines (Daemen et al., 2013) and TCGA (Akbani et al., 2014) in 421 tumours are observed systematically for their correlation of mRNA expression and protein abundance (for detailed information see materials part). Figure 1 shows sample size and gene number of analysis data from TCGA breast tumours and CCLE breast cell lines, and correlation analysis of mRNA-protein flowchart. The detailed sample's annotation is provided in Supplementary Table 1. A quantitative transcriptomics analysis (Array-based) PAM50 is used to classify breast cancer sample subtypes in tumours and cell lines (Jiang et al., 2016) . The correlation of mRNA-protein is compared in both cell and tumour samples. Systematically correlation comparison of mRNA-protein are investigated between cells and tumours in breast cancer and its four subtypes with three assessments:
• Comparing mRNA-protein correlation in a single gene. Several probes (the same gene) vs. its accordance protein is analysed in breast cancer cells. A protein from several antibodies vs. its gene expression is analysed in breast cancer tumours.
• Protein abundance with its mRNA distribution is detected in different subtype of breast cancer.
• The genes with high mRNA-protein correlation are investigated further in four types of breast cancer.
The pathway enrichment, the drug-targeted genes and the up-regulation genes in breast tumours (comparing tumours with adjacent normal groups in TCGA by paired t-test, significant differential expression gene by threshold p < 0.05, fold change >1.5),using the STRING tool of protein-protein network for each type of breast cancer are investigated.
Probe sets and antibodies for correlation coefficient variation of mRNA-protein
To observe the correlation variation for expression levels of mRNA and protein for different probe sets, we used 300 probesets corresponding to 63 genes to calculate their correlation with protein levels across 33 breast cell lines. Correlation of probe-protein exhibits large variation. ( (Table 1) for breast cancer has validated the existence of a nonlinear relationship. The percentages of genes with high correlation >0.5 in each subtype has a range of 0.21 to 0.67 (Table 1) . The results illustrate a wide variation of correlations of mRNA-protein among cells and tumours in breast cancer. Detailed comparison of gene probe sets and antibodies has potential benefits to improve specificity and affinity from gene to protein when designing a biology experiment.
mRNA-protein correlation comparison from cells to tumours in breast cancer and its subtypes
We further investigated the correlation similarities of mRNA-protein between 33 breast cancer cell lines and 421 breast tumours among 47 overlapping genes. For each protein in tissue samples, the corresponding antibody-mRNA maximum correlation is chosen (Figure 3 In luminal A, however, the fitted linear regression model on correlation values was non-significant p = 0.249 (Figure 3(c) ). This observation was due to a small sample size of n = 3 in luminal A cancer cells. Another important finding of our study is that the gene set with a high correlation (r > 0.5, p < 0.01) of mRNA-protein in four subtypes is closely related to drug target genes in both breast cell lines and tumours (Figure 3 (a) red dots, Supplementary Table 4) . These include clinically relevant targets, such as: ESR1, EGFR, AR, PGR, and ERBB2. A high mRNA-protein correlation was observed also for: BCL2, GATA3, CCNB1, CDH1, ACACA, IGFBP2, RAB25 and CCND1 (Figure 3(a) red dots) . Furthermore, discovering the existence of different high correlation gene lists of mRNA-protein among the four subtypes has proven to be a particularly meaningful finding (for detailed result see Supplementary Figure 3 
Pathway and drug target analysis for high correlation of mRNA-protein for breast cancer subtypes
We attempted to identify concordance proteins, which have high correlation with mRNA in each subtype of breast cancer. A functional enrichment analysis of significant genes was performed in each subtype. The gene list with high correlated mRNA-protein (r > 0.5, p-value < 0.05) in cell line or tumour tissue was selected for further gene enrichment analysis. Large gene lists were mapped into the Functional Annotation tool, DAVID (https://david.ncifcrf.gov/). The significant identified pathways by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database were selected by a threshold p < 0.01. Next, these gene lists were mapped into STRING (a visualising tool for the functional protein association networks, http://string-db.org/) for seeking molecular interactions. Drug targeted genes were annotated by Drug Bank database (http://www.drugbank.ca/drugs). Genes with high correlation of mRNA and protein and over expression in tumours can provide us evidence for discovery of potential drug targets in cancer therapy.
In the basal-like subtype, 69 genes with highly correlated mRNA-protein (r > 0.5, p-value < 0.05) from 81 tumours and 15 cell lines were selected for network analysis. Among them, 17 genes (ARID1A, ATM, BCL2L11, CASP8, EN1, FGFR1, ITGA2, KIAA1303, MSH2, NF2, NRG1, PECAM1, PRDX1, RAD50, SERPINE1, SNAI1, TSC2) uniquely regulated their related proteins in basal-like subtype (Supplementary  Table 5 (a)). 31 of the 69 genes were previously known drug targets by Drug Bank annotation. When comparing tumours with adjacent normal groups in TCGA, 9 out of 69 were found to be over expressed in tumours (paired t-test, p < 0.05, fold change > 1.5) (Supplementary Table 6 ). This includes genes RAD50, ATM, EN1, NOTCH3, ERBB3, CLDN7, RAD50, RAB25 and COL6A1, CCND1, ATM and SRC, of which CCND1, ATM, and SRC are known drug targets based on Drug Bank annotation. These genes are visualised in Figure 4 (a) using the Cytoscape online tool. The 69 basal-like network of genes contains 672 interactions. Nodes with yellow colour are drug targetable genes and a red circle around particular nodes depicts over expressed genes by comparison of tumour vs. normal, which indicates potential drug targets. Functional enrichment analysis of 69 genes in DAVID indicated 10 relevant pathways in primary breast cancer in 45 significant pathways, among which ErbB, p53 and mTOR signalling pathways were most significant (Figure 4(e) ). In addition, the B cell receptor signalling pathway was significant only in basal-like subtype, when compared to the pathway analyses in other subtypes. The number of pathways across the network for each individual gene was calculated (the size of node in Figure 4(a) ). MAPK1, PIK3CA and AKT1 were the top 3 in basal like subtype, which were involved in 45, 34 and 30 signalling pathways respectively.
In luminal A subtype, 44 genes with high correlation of mRNA-protein were analysed. 25 of them were known drug targets based on Drug Bank annotation and 6 out of 44 were found to be up regulated. Two potential new drug targets (PREX1 and INPP4B, over expression in tumours) have been identified. These genes were significantly regulated and also over expressed in tumour samples (Figure 4(b) ). Based on KEGG pathway analysis, a total of 21 pathways were found to be related to luminal A genes, among which T cell receptor signalling pathways, focal adhesion and cell cycle were observed. High frequency genes involved were:PIK3CA, AKT2 and BRAF involved with 14, 10 and 12 pathways, respectively. ErbB signalling pathway was the most significant pathway for this gene list. The focal adhesion signalling pathway was observed only in luminal A subtype (Figure 4(f) ).
In luminal B subtype, 51 genes with high correlation of mRNA-protein were investigated, of which 28 genes were known drug targets and identified by Drug Bank. Of the 28, six genes (YWHAZ, INPP4B, PREX1, STAT3, CHD1 and SAMD3) were up regulated in tumours and were identified as potential target genes in our study (Figure 4(c) ). According to KEGG pathway by DIVID analysis, 37 significant pathways in luminal B were identified, which were related to ErbB, Insulin mTOR, neurotrophin and GnRH signalling pathways (Figure 4(g) ). Top pathway crossing genes MAP2K1, EGFR, AKT1, RAF1, CCND1, ERBB2, p53 and PRKCA are shown (more than 19 pathways) in Figure 4(g) .
In HER2 subtype, 44 genes with high correlation of mRNA-protein were investigated, in which 21 genes were known drug targets by Drug Bank annotation.10 out of the 21 genes (INPP4B, PARP16, EREG, ERBB3, COMT, STAT3, CLN7, NOTCH3, MST1 and PXN) showed upregulation in tumours compared to normal tissue (p < 0.05, folder change > 1.5) and were suggested as potential targets for HER2 subtype patient therapy (Figure 4(d) ). Functional enrichment analysis of 44 genes showed 10 significant pathways (p < 0.01), including ErbB, p53, endometrial and VEGF signalling pathways (Figure 4(e) ). Chemokine signalling pathway and Wnt pathway were only observed for HER2 subtype, compared with other subtypes. The top pathway crossing genes MAPK1 (82/82), MAP2K1 (61/82), PRKCA (57/82) and MAPK8 (43/82) are highlighted in Figure 4 (h). 3 Discussion and conclusion mRNA plays a central role in gene control and interaction. Attempts to correlate protein abundance with mRNA expression levels have had mixed results. Since mRNA is eventually translated into protein and one might assume that some correlation should exist between the levels of mRNA and associated protein.
The high-quality data for large-scale studies, microarray and RPPA, provide an opportunity to detect the relationship between mRNA expression and protein abundance. In this study, the correlation between protein abundances and their related gene expression levels was investigated in cell lines and tumours in breast cancer, with specificity to its subtypes. The main aim was to distinguish subtype specific features around mRNA-protein in order to identify their pathways and possible drug targets.
Correlation of mRNA-protein discussion for breast cancer
We observed a weak correlation between mRNA and protein abundances in breast cancer cell lines and tumours. The average correlation coefficient of mRNA and protein was 0.245 in breast cancer taking into account antibody and probe variation. This result is concordant with previous studies. In an experiment of haploid vs. diploid yeast cells, a moderate correlation (r = 0.46 to 0.68) between the relative abundance in proteins and mRNAs was reported (Lundberg et al., 2010) . Schwanhäusser et al. (2011) observed that the mRNA and protein corresponding half-lives have no correlation owing to non-synthesis rates of mRNAs and proteins variation. Furthermore, the concentration of proteins may vary under different growth conditions. Regulation at the level of mRNA serves as a switch, whereas downstream transcriptional regulation functions as a rheostat to fine tune protein abundance. The distribution of expression of mRNA and protein exhibits a nonlinear relationship. Based on our observations, relative protein abundances were only partially predicted by relative mRNA abundances. Theory governing the relationship between mRNA and protein requires further analysis and validation in future studies (Eric et al., 2007) . Multiple reports (Greenbaum et al., 2003; Vogel and Marcotte, 2012; Vogel et al., 2010) have attempted to explain the poor correlation observed between mRNA and protein abundance. Three reasons have been postulated assumed mutual exclusivity. First, complicated signal amplification must occur by varied post-transcriptional mechanisms involved in turning mRNA into protein that are not yet sufficiently well-defined. Second, proteins may differ substantially in their in vivo half-lives; proteins tend to show higher differences than expected by chance at different time points (Beck et al., 2011; Schwanhäusser et al., 2011) . Third, there is a large variation of control mechanism from mRNA translation into protein that limits our ability to get a clearer picture. In a recent paper (Mertins et al., 2016) , researchers observed the effects of somatic mutations on these genetic alterations in the proteomic landscape and searched for a connection between the loss of genes and the elevated expression of other genes. mRNA sequence lengths, amino-acid properties, upstream open reading frames and secondary structures in the 5ʹ untranslated region (UTR) were the strongest individual correlates of protein concentrations. mRNAs have been associated with subtle regulation of protein expression levels, and are not known to cause large expression changes (Baek et al., 2008) .
To detect the similarity between tumour and cell-line specific mRNA and protein, correlation of mRNA-protein of 47 overlapping genes between cell-line and tumour was compared in our study. 18 of 47 genes with a high correlation of mRNA to protein in breast cancer cell lines were found to have similar concordance in breast tumours. The signal transduction concordance of mRNA-protein was r 2 = 0.723 between cells and tumours in breast cancer via a linear simulation. A similar phenomena was observed in four subtypes of breast cancer except in luminal A, which was confounded by a low sample size. Although low correlation of mRNA-protein existed in both breast cancer cells and breast tumours, cell lines were representative of tumour features at transcript and protein levels.
Important drugs targets and pathway in different subtype of breast cancer
Correlation comparison of mRNA and protein abundance in different subgroups of breast cancer, suggests numerous potentially targetable alterations for subtypes. Genes with high correlation of mRNA-protein shared functional properties for different subtypes of breast cancer. The highest correlation of probe-protein, 0.9, for gene ESR1 can be observed in luminal B, and the highest PGR correlation of mRNA-protein, 0.772, by antibody PR-R-V was observed in Luminal A. The high correlation of Her2 probe-protein was found to be 0.919 for luminal B subtype and 0.778 for HER2amp subtypes in tumours, but only 0.26 in basal like subtype. The result is concordant with clinical pathologic observations for HER2+ disease. EGFR displays a high correlation of mRNA-protein (using specific antibodies) in four subtypes: basal like was 0.74 by EGFR-R-V antibody, luminal A was 0.5032 by EGFR-R-V antibody, luminal B was 0.65 by EGFR_pY1068-R-C and HER2 amplification was 0.84 by EGFR-R-V antibody. Genes with high correlation of mRNA are potential biomarker candidates for targeted therapy in each subtype of breast cancer.
Distinct molecular pathways have been observed in each of the breast cancer subtypes (Akbani et al., 2014; Stuhlmiller et al., 2014) . We observed that highly correlated gene-proteins were significantly involved in VEGF and mTOR signalling pathways in TNBC. These results confirm the interest of targeting pathway VEGF and mTOR in ongoing clinical trials in TNBC patients (Burstein et al., 2008; Ellard et al., 2009) . The genes SRC, CCND1, and ATM with high correlation of mRNA-protein were significantly up regulated and thus are potential drug targets for TNBCs. These results have been consistently observed in the literature (Glénisson et al., 2012; Millis et al., 2015) . EGFR maintains a high signal transduction of 0.61 from mRNA to protein and is an important drug target in many cancers; however, it is not over expressed in TNBC when compared to adjacent normal (p < 0.05). Treatments of TNBC with Cetuximab, EGFR targeted therapies, has not been successful (Carey et al., 2012) and proteomic and genomic features of this subtype are still unknown.
Our results provide evidence of PREX1 over expression in luminal A\B subtype. Multiple studies have shown up regulation of this gene in both tumour and cell line samples of breast cancer (Sosa et al., 2010; Dillon et al., 2015) . High correlation of PREX1 with ER indicated over expression of this gene as a specific genetic feature of breast cancer patients with ER positive status (Ebi et al., 2013) . Furthermore, previous studies have reported correlation of PREX1 with PI3K/AKT, Rac1 and MEK/ERK signalling pathways and highlighted the effect of PREX1 in activation and suppression of these pathways (Sosa et al., 2010) . In our study, protein expression of PREX1 was significantly correlated with its mRNA expression (r = 0.8 in luminal B and r = 0.67 in luminal A; p-value < 0.05) and was transcriptionally up regulated in luminal tumours. Thus, similar to other studies (Ebi et al., 2013; Sosa et al., 2010) , our analysis designates PREX1 as a potential novel drug target for luminal breast cancer. Although over expression of PIK3CA was not seen in luminal A pathway analysis, we found PIK3CA to be involved in 14 signalling pathways related to breast cancer. PIK3CA has been shown to have activation mutations, particularly in luminal subtypes (Miller et al., 2011) . Luminal B data suggested up regulation of gene YWHAZ, as well as high correlation of its mRNA and protein level. Thus, we suggest more investigation on YWHAZ as a potential drug target for novel targeted therapy. Over expression of YWHAZ has been linked to advanced breast cancer incidence, shorter survival time and poor treatment response to tamoxifen inpatients with ER positive status (Frasor et al., 2006) .
Patients with HER2subtype breast cancers, which are indicated mainly by HER2 amplification, have been treated successfully with targeted regimens (Tai et al., 2010) . Up regulation and significant correlation found in STMN1, MST1R, CLDN7, EREG, COMT, PARP16, INIPP4B, STAT3 and NOTCH3 with their related protein demonstrated their potential applicability in the advancement of novel HER2 targeted therapy. In particular, correlation between over expression of MSTR1 and progression in breast cancer tumours has been reported previously (Kretschmann et al., 2010) . In our study, phosphoprotein c-Met (pY1235) was regulated by gene MSTR1, suggesting its potential benefit in targeted treatment. This finding bolsters those of a previous study (Kretschmann et al., 2010) on importance of MSTR1 (Ron) and its potential benefit in new therapeutic avenues. The gene SRC is a particular target of interest. In our results, it maintained a high mRNA/protein correlation across all types of breast cancer cell lines, and in tumour samples, a large mRNA/protein correlation was seen in HER2 tumours. It is noted that the small sample size in cell lines may affect analysis results. Thus, further investigation in future research is needed.
In conclusion, the correlation and distribution of mRNA expression and protein abundance are systematically investigated and compared for breast cancer and its subtypes in cells and tumours. Multiple probes and antibodies variation for correlation of mRNA-protein in breast cancer are observed and discussed. The nonlinear relation of the distribution of mRNA expression and protein abundance is shown and discussed for breast cancer and its subtypes. The high correlation of mRNA-protein of breast tumours and cell lines are further analysed in detail. Those subtype specific gene lists of high correlation mRNA-protein are found for the first time in cell lines and tumour tissues for breast cancer. Those genes have overlap with drug targets used in the clinic. The detailed pathway and network analyses show important gene connections and involved pathways for subtypes of breast cancer, and potential genes for targeted therapy are recommended. Similarities in mRNA-protein correlation in cell lines and tumours provide us evidence that cell line models can be used to predict drug response in tumour tissue by both mRNA and protein. Considerable work still lies ahead to understand the apparent coupling between the different processes that are required to synthesise mRNA and to maintain protein expression levels.
Furthermore, there open-ended questions still remain in regard to the specificity of translation regulation, feedback and coupling between regulatory processes (such as, transcription, translation and degradation). Advance connection between mRNA and protein provides a clear path towards addressing these issues, especially the ability to survey proteome turnover and gene function.
Materials

Microarrays and phosphoproteins RPPA data
Tumour tissue data and annotations were directly downloaded from The Cancer Genome Atlas (TCGA) data portal (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp). mRNA profile of 17,814 genes and 593 primary breast cancer samples by the AgilentG4502A_07_3 platform test was collected. Breast cancer cell lines were extracted from CCLE (http://www.broadinstitute.org/ccle) for 56 samples. mRNA expression of cell lines were tested by Affymetrix HU133 PLUS 2.0 for 54,675 probe sets representing more than 39,000 transcripts.
Protein and phosphoprotein expression of tumours and cell lines were measured by reverse phase protein array (RPPA), a high-throughput antibody-based technique. Hundreds to thousands of lysates are arrayed in dense regular grids and each grid is probed with a different antibody. Protein and phosphoprotein levels are detected by the different antibodies reorganisation. A protein has several antibodies accordance and the annotation of antibody and gene names match refers to the paper (The Cancer Genome Atlas Research Network, 2014). RPPA profiles of breast tumours were extracted from TCGA website for 421 patients with 254 high-quality antibodies that target 191 total proteins and 49 post-translationally modified proteins. As a result, multiple antibodies were mapped to one gene. RPPA protein expression for cell lines is originated from the Gordon Mills lab at MD Anderson (Daemen et al., 2013) . It includes 70 proteins for 49 breast cancer cells (Nagaraj et al., 2011) , in which 32 are phosphoprotein expression. Due to diversity of tumour subtypes in breast cancer, it is essential to determine specific molecular features of subtypes for better insight of targeted therapy. Classification of cell lines and tumour tissues into four subtype of basal-like, luminal A, luminal B, and HER2+ was based on unsupervised analysis of ER, PR and HER2 protein status advance. In addition, PAM50 was used to classify those samples missing ER, PR, and HER2 proteins status. This analysis was performed in our previous study (Reference deleted to keep manuscript anonymous).
Statistical method
Pearson correlation and linear regression model was used to explore relation between genomic and proteomic data. Cluster analysis was performed to study patterns between cell line and TCGA tumour data and to assess protein and mRNA ratio. Differential gene expression analysis was performed using paired T-test over 60 pairs of normal and tumour tissue from TCGA data portal (Supplementary Table 1(c) provides samples' annotation).
Pathway enrichment analysis
Gene functional enrichment analysis and pathway analysis was carried out by DAVID tool (Bioinformatics Resources 6.7) (Huang et al., 2009 ). The main pathways are extracted from KEGG database (Kyoto Encyclopedia of Genes and Genomes) result set with p-values < 0.01, which is identified from DIVID.
Network visualisation
String 9.1 (http://string-db.org/), as the Search Tool for the Retrieval of Proteins Interacting, is used for protein interaction analysis. Network visualisation is built by using online tool Cytoscape 3.1.0 (Shannon et al., 2003) .
Data availability
Gene expression for platform AgilentG4502A_07_3 and RPPA dataset for breast tumours are available from TCGA data portal http://cancergenome.nih.gov/. Gene Chip dataset for Affymetrix Human Genome U133 Plus 2.0 Array in the Cancer Cell Line Encyclopedia (CCLE) are available from Gene Expression Omnibus (GEO) under accession number GSE36133. RPPA expressions of breast cancer cells are assessable from supplementary of literature (Daemen et al., 2013) .
Supplementary material is available on request from the corresponding author, Lijun Cheng.
